FTO and cancer: Low m6A level, as an independent prognostic indicator, was found to be associated with cancer progression and poor outcome through screening 286 cervical cancer samples, and augmenting m6A modification with the FTO inhibitor MA2 suppressed the tumour development in mouse models.121, 122